בינוקריט 40000 יחבל  1 מל ישראל - עברית - Ministry of Health

בינוקריט 40000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

סנדוסטטין 30 מג LAR ישראל - עברית - Ministry of Health

סנדוסטטין 30 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין  20 מג LAR ישראל - עברית - Ministry of Health

סנדוסטטין 20 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין  10 מג LAR ישראל - עברית - Ministry of Health

סנדוסטטין 10 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

זיפאדהרה 210 מ"ג ישראל - עברית - Ministry of Health

זיפאדהרה 210 מ"ג

eli lilly israel ltd - olanzapine 210 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

זיפאדהרה 300 מ"ג ישראל - עברית - Ministry of Health

זיפאדהרה 300 מ"ג

eli lilly israel ltd - olanzapine 300 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

זיפאדהרה 405 מ"ג ישראל - עברית - Ministry of Health

זיפאדהרה 405 מ"ג

eli lilly israel ltd - olanzapine as pamoate monohydrate 405 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

פרינג'קט ישראל - עברית - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial - ferinject is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. the diagnosis must be based on laboratory tests.

בינוקריט 8000 יחבל  0.8 מל ישראל - עברית - Ministry of Health

בינוקריט 8000 יחבל 0.8 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 8000 iu / 0.8 ml - erythropoietin

סיגניפור לאר 20 מג ישראל - עברית - Ministry of Health

סיגניפור לאר 20 מג

medison pharma ltd - pasireotide as embonate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as embonate 20 mg/vial - pasireotide